X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds from the offering to advance clinical development of JANX007, which is designed to target PSMA. It is being evaluated in the phase I clinical trial studies for the treatment of Metastatic Castration-resistant Prostate Cancer.
Lead Product(s): JANX007
Therapeutic Area: Oncology Product Name: JANX007
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $296.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 29, 2024
Details:
The Company intends to use the net proceeds from the offering to advance the clinical development of JANX007, designed to target PSMA. It is being evaluated in the clinical trial studies with metastatic castration-resistant prostate cancer.
Lead Product(s): JANX007
Therapeutic Area: Oncology Product Name: JANX007
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 27, 2024
Details:
JANX007 is a novel Tumor Activated T Cell Engager (TRACTr) that targets PSMA and is being investigated in a Phase 1 clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): JANX007
Therapeutic Area: Oncology Product Name: JANX007
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
JANX008 is a TRACTr that targets EGFR and is being studied in a Phase 1 trial for the treatment of multiple solid cancers including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Lead Product(s): JANX008
Therapeutic Area: Oncology Product Name: JANX008
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
JANX008 is a double-masked TRACTr in which the EGFR-binding domain and the T cell-specific binding domain (CD3) is masked. It might prove to be an attractive solid tumor therapeutic.
Lead Product(s): JANX008
Therapeutic Area: Oncology Product Name: JANX008
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Details:
JANX007 is a prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) and is the first product candidate utilizing Janux’s TRACTr platform to be administered in humans. JANX007 has the potential for tumor-selective T cell activation and tumor cell killing.
Lead Product(s): JANX007
Therapeutic Area: Oncology Product Name: JANX007
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
JANX007 is the Company’s lead novel T cell engager (TCE) therapeutic from its TRACTr platform. Janux plans to initiate a Phase 1 clinical trial for JANX007 in the second half of 2022.
Lead Product(s): JANX007
Therapeutic Area: Oncology Product Name: JANX007
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008), a novel Tumor Activated T Cell Engager therapeutic exhibit enhanced safety and PK properties relative to unmasked T cell engagers.
Lead Product(s): JANX007
Therapeutic Area: Oncology Product Name: JANX007
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
The company’s TRACTr technology is engineered to overcome limitations of current immuno-oncology T-cell therapies, primarily dose-limiting toxicities, poor pharmacokinetic profiles, and limited efficacy.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Avalon Ventures
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 21, 2021
Details:
The proceeds of the financing will help support the advancement of Janux’s pipeline of next generation T cell engager immunotherapies, including a PSMA-TRACTr, EGFR-TRACTr, and TROP2-TRACTr, into initial proof of concept clinical trials.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: BVF Partners L.P
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
